209 related articles for article (PubMed ID: 19718394)
21. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
J Bone Miner Metab; 2005; 23(3):238-42. PubMed ID: 15838627
[TBL] [Abstract][Full Text] [Related]
22. Alendronate improves QOL of postmenopausal women with osteoporosis.
Kawate H; Ohnaka K; Adachi M; Kono S; Ikematsu H; Matsuo H; Higuchi K; Takayama T; Takayanagi R
Clin Interv Aging; 2010 Apr; 5():123-31. PubMed ID: 20458350
[TBL] [Abstract][Full Text] [Related]
23. Alfacalcidol Increases the Therapeutic Efficacy of Ibandronate on Bone Mineral Density in Japanese Women with Primary Osteoporosis.
Nakamura Y; Suzuki T; Kamimura M; Ikegami S; Uchiyama S; Kato H
Tohoku J Exp Med; 2017 Apr; 241(4):319-326. PubMed ID: 28458336
[TBL] [Abstract][Full Text] [Related]
24. Three-year experience with combined treatment with alendronate and alfacalcidol in Japanese patients with severe bone loss and osteoporotic fracture.
Iwamoto J; Sato Y; Uzawa M; Takeda T; Matsumoto H
Ther Clin Risk Manag; 2011; 7():257-64. PubMed ID: 21753888
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of alendronate in postmenopausal type 2 diabetes mellitus.
Ikeda T; Manabe H; Iwata K
Diabetes Metab; 2004 Sep; 30(4):355-8. PubMed ID: 15525879
[TBL] [Abstract][Full Text] [Related]
26. Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: a multicenter, randomized, comparative study.
Soen S; Yamamoto K; Takeuchi T; Tanaka Y; Tanaka S; Ito M; Nakano T; Hagino H; Hirakawa A; Matsumoto T
J Bone Miner Metab; 2020 Jul; 38(4):511-521. PubMed ID: 31970477
[TBL] [Abstract][Full Text] [Related]
27. Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
Yonsei Med J; 2005 Dec; 46(6):750-8. PubMed ID: 16385649
[TBL] [Abstract][Full Text] [Related]
28. A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group.
Shiraki M; Kushida K; Fukunaga M; Kishimoto H; Taga M; Nakamura T; Kaneda K; Minaguchi H; Inoue T; Morii H; Tomita A; Yamamoto K; Nagata Y; Nakashima M; Orimo H
Osteoporos Int; 1999; 10(3):183-92. PubMed ID: 10525709
[TBL] [Abstract][Full Text] [Related]
29. Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT) - 02.
Orimo H; Nakamura T; Fukunaga M; Ohta H; Hosoi T; Uemura Y; Kuroda T; Miyakawa N; Ohashi Y; Shiraki M;
Curr Med Res Opin; 2011 Jun; 27(6):1273-84. PubMed ID: 21554143
[TBL] [Abstract][Full Text] [Related]
30. Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA).
Matsumoto T; Yamamoto K; Takeuchi T; Tanaka Y; Tanaka S; Nakano T; Ito M; Tomomitsu T; Hirakawa A; Soen S
J Bone Miner Metab; 2020 Jul; 38(4):522-532. PubMed ID: 32140784
[TBL] [Abstract][Full Text] [Related]
31. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.
de Nijs RN; Jacobs JW; Lems WF; Laan RF; Algra A; Huisman AM; Buskens E; de Laet CE; Oostveen AC; Geusens PP; Bruyn GA; Dijkmans BA; Bijlsma JW;
N Engl J Med; 2006 Aug; 355(7):675-84. PubMed ID: 16914703
[TBL] [Abstract][Full Text] [Related]
32. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
Saag KG; Shane E; Boonen S; Marín F; Donley DW; Taylor KA; Dalsky GP; Marcus R
N Engl J Med; 2007 Nov; 357(20):2028-39. PubMed ID: 18003959
[TBL] [Abstract][Full Text] [Related]
33. Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
Yonsei Med J; 2004 Aug; 45(4):676-82. PubMed ID: 15344210
[TBL] [Abstract][Full Text] [Related]
34. An investigation of the predictors of bone mineral density and response to therapy with alendronate in osteoporotic men.
Drake WM; Kendler DL; Rosen CJ; Orwoll ES
J Clin Endocrinol Metab; 2003 Dec; 88(12):5759-65. PubMed ID: 14671165
[TBL] [Abstract][Full Text] [Related]
35. Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss.
Reginster JY; Lecart MP; Richy F
J Rheumatol Suppl; 2005 Sep; 76():21-5. PubMed ID: 16142847
[TBL] [Abstract][Full Text] [Related]
36. Experience with alendronate treatment for four years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures.
Iwamoto J; Sato Y; Uzawa M; Takeda T; Matsumoto H
Ther Clin Risk Manag; 2010 Dec; 6():593-600. PubMed ID: 21206758
[TBL] [Abstract][Full Text] [Related]
37. Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis.
Iwamoto J; Takeda T; Ichimura S; Matsu K; Uzawa M
J Orthop Sci; 2003; 8(4):532-7. PubMed ID: 12898306
[TBL] [Abstract][Full Text] [Related]
38. Overcoming resistance to bisphosphonates through the administration of alfacalcidol: results of a 1-year, open follow-up study.
Gaál J; Bender T; Varga J; Horváth I; Kiss J; Somogyi P; Surányi P
Rheumatol Int; 2009 Nov; 30(1):25-31. PubMed ID: 19308412
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of bone remodelling parameters after one year treatment with alendronate in postmenopausal women with osteoporosis.
Kučukalić-Selimović E; Valjevac A; Hadžović-Džuvo A; Skopljak-Beganović A; Alimanovic-Alagić R; Brković A
Bosn J Basic Med Sci; 2011 Feb; 11(1):41-5. PubMed ID: 21342141
[TBL] [Abstract][Full Text] [Related]
40. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
